Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimizing Haploidentical Transplantation for Severe Aplastic Anemia (CHAMP)
NCT02918292Phase 2Completed
- Sponsor
- Medical College of Wisconsin
- Start
- Jul 2017
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in aplastic anemia, sponsored by Medical College of Wisconsin. Primary endpoint: Overall Survival at 1 year. Started Jul 2017; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT02918292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02918292.